BiotechTube

Icosapent

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypertriglyceridemia

Conditions

Hypertriglyceridemia

Trial Timeline

Feb 14, 2020 → Jul 14, 2021

NCT ID
NCT04221217

About Icosapent

Icosapent is a phase 3 stage product being developed by Mochida Pharmaceutical for Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04221217. Target conditions include Hypertriglyceridemia.

What happened to similar drugs?

1 of 20 similar drugs in Hypertriglyceridemia were approved

Approved (1) Terminated (0) Active (19)
🔄Placebo + Ethyl IcosapentateSumitomo PharmaPhase 3
🔄Omega-3-Acid Ethyl Esters 90 Soft Capsules + Corn OilJiangsu Hengrui MedicinePhase 3
✅rosuvastatinAstraZenecaApproved
🔄Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4gAstraZenecaPhase 3
🔄Epanova + Olive OilAstraZenecaPhase 3
🔄AZD0585 + AZD0585 placeboAstraZenecaPhase 3
🔄ABT-143 + simvastatinAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04221217Phase 3Completed

Competing Products

20 competing products in Hypertriglyceridemia

See all competitors
ProductCompanyStageHype Score
LY3875383 + PlaceboEli LillyPhase 1
21
ZYH7 + ZYH7 + ZYH7 + FenofibrateZydus LifesciencesPhase 2
35
Solbinsiran + PlaceboEli LillyPhase 2
42
Placebo + Ethyl IcosapentateSumitomo PharmaPhase 3
40
Omega-3-Acid Ethyl Esters 90 Soft Capsules + Corn OilJiangsu Hengrui MedicinePhase 3
36
warfarin + omefas + omega-3-acid ethyl estersAstraZenecaPhase 1
29
rosuvastatinAstraZenecaApproved
43
Simvastatin + acetylsalicylic acid (ASA) + omefasAstraZenecaPhase 1
29
Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4gAstraZenecaPhase 3
40
Epanova (4 g) and Lovaza (4 g) + Lovaza (4 g) and Epanova (4 g)AstraZenecaPhase 2
35
rosuvastatin 40 mg tablet + Epanova™ QD (2 x 1 g capsules) + Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose + Multiple (20) oral doses of 2 g Vascepa® every 12 hoursAstraZenecaPhase 1
29
placebo + omefas + omefas + omefasAstraZenecaPhase 2/3
38
Epanova + LovazaAstraZenecaPhase 1
29
Epanova + Olive OilAstraZenecaPhase 3
40
AZD0585 + AZD0585 placeboAstraZenecaPhase 3
40
ABT-143 + simvastatinAstraZenecaPhase 3
40
MaravirocPfizerPhase 1
29
torcetrapib/atorvastatin + atorvastatinPfizerPhase 3
40
Icosapent (MND-2119) + Icosapent (EPADEL CAPSULES 300)Mochida PharmaceuticalPhase 3
40
REGN1500 + placeboRegeneron PharmaceuticalsPhase 1
29